Indian Pharma News - Latest Updates & Headlines
Indian Pharma Industry is likely to grow at a steady pace of 10% in FY26: Report
New Delhi, June 12: Pharmaceutical companies in India are expected to grow steadily at a rate of approximately 10 per cent in FY26, driven by price increases and the launch of new products, according to a report by ICICI Securities.
Trump's Executive Order on reducing prescription drug prices will have limited impact on Indian pharma companies: Crisil Ratings
New Delhi, June 3: US President Donald Trump's executive order on reducing prescription drug prices will have a limited impact on Indian pharma companies, according to a report by Crisil Ratings.
Mankind Pharma's Q4 net profit drops 10.7 pc
Mumbai, May 21: Mankind Pharma on Wednesday reported a 10.7 per cent year-on-year (YoY) decline in net profit to Rs 420.8 crore for the quarter ended March 2025 (Q4 FY25), down from Rs 471.2 crore in the same quarter last fiscal.
From generic drugs to vaccines, Indian pharma industry is transforming lives worldwide
New Delhi, May 18: India has transformed itself into a global health leader in terms of affordability, innovation, and inclusivity over the past decade.
India's pharma sector ranked 3rd in world, leads in affordable drugs
New Delhi, May 18: India's pharmaceutical industry, which has emerged as the largest supplier of affordable generic medicines, is poised to grow at 7.8 per cent year-on-year in April 2025 driven by strong demand and new products, according to experts at India Ratings.
Generic pharma companies unlikely to be impacted by Trump's order to cut Rx drug prices: Report
New Delhi, May 16: Generic drug companies in India are not expected to be affected by US President Donald Trump's new order to bring the prices for prescription (Rx) drugs in line with other developed nations, according to a report by HDFC Securities.
India pharma market sees 7.4 pc growth in April over surge in chronic therapies
New Delhi, May 15: Indian pharma market (IPM) has seen a 7.4 per cent year-on-year (YoY) growth in April due to a surge in chronic therapies, according to a report.
MoS Margherita oversees signing of MoU on Recognition of the Indian Pharmacopoeia with Fiji
Suva, May 13: Union Minister of State for External Affairs Pabitra Margherita on Tuesday witnessed the signing of an MoU on the Recognition of the Indian Pharmacopoeia.
Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report
New Delhi, May 10: The Indian Pharmaceutical Market continued its upward momentum in April 2025, registering a strong 7.8 per cent year-on-year growth with total sales reaching Rs 19,711 crore, according to a report by Pharmatrack.
Trump's new executive orders may hit Indian Pharma exports, reshape global drug supply chains: Report
New Delhi, May 7: The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for Indian pharmaceutical companies, especially those operating in the U.S. generic drug market, according to a report by Nuvama Research.
Zydus receives approval from the US drug authority to produce cholesterol-lowering tablets
New Delhi, April 30: Indian multinational pharmaceutical company, Zydus Lifesciences Limited, has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets.
Indian pharma giants target bigger share of $145 billion US cancer drug market
New Delhi, April 18: Indian pharmaceutical companies are ramping up efforts to expand their footprint in the lucrative US oncology generics market, which is currently valued at $145 billion and growing at a robust pace of 11 per cent annually, according to a new report.
Russia denies strike on Indian pharma warehouse in Kyiv, blames Ukrainian missile
Moscow, April 18: Russia on Thursday dismissed Ukraine's accusation that its military attacked the warehouse of an Indian pharmaceutical company in Kyiv.
'Factually incorrect': Dr Reddy's denies report on 25 pc workforce cost cuts, laying off highly-paid staff
New Delhi, April 14: Pharmaceutical major Dr Reddy's Laboratories on Monday denied media reports that claimed that the company is planning a 25 per cent reduction in workforce costs and laying off high-earning employees.
Who's going to pay price to bring back manufacturing in US, asks Biocon MD amid possibility of tariffs on pharma
New Delhi, April 11: Siddharth Mittal, CEO and Managing Director of Biocon Limited, on Friday questioned who would pay the price to shift their establishments to the US where pharma manufacturing costs are higher than in India and China.
Will announce a major tariff on Pharma shortly, says US President Donald Trump
Washington DC, April 9: US President Donald Trump continues to be belligerent on his policy of reciprocal Tariffs despite strong opposition both within the US and outside. On Tuesday night (local time), the US President announced that Tariffs on the Pharma sector were coming soon. The sector has so far been exempt from the Tariffs.
Vijaya Diagnostic shares slip further amid broader market correction
New Delhi, April 4: Vijaya Diagnostic Centre Limited’s stock came under pressure on Friday as part of the broader market correction, ending the day lower by Rs 26.15 apiece or 2.7 per cent at Rs 944.55 on the National Stock Exchange (NSE).
India in active talks with domestic pharma exporters amid new US tariff threat
New Delhi, April 4: The Commerce Ministry is in active talks with Indian pharmaceutical exporters amid growing concerns over possible US tariffs on the sector, which was exempted in the first tranche of reciprocal tariffs by US President Donald Trump.
Pharma companies likely to see up to 16 pc sales growth in FY25: Centrum Report
New Delhi, April 4: India's leading pharmaceutical companies are expected to report strong sales growth of up to 16 per cent year-on-year (YoY) in the financial year 2024-25, according to a report by Centrum Institutional Research.
India's pharmaceutical products may be subject to duties in future actions under US Trade Expansion Act of 1962: Report
New Delhi, April 3: The recent imposition of a 27 per cent reciprocal tariff on Indian exports by the United States, while exempting the pharmaceutical sector, has raised concerns about potential future trade restrictions on drug exports.
Indian pharmaceutical exports get reprieve from Trump's reciprocal tariffs
New York, April 3: Because of the importance of India’s pharmaceuticals to US healthcare, those exports will get a reprieve from President Donald Trump’s reciprocal tariffs, according to the White House.
US tariffs: Global brokerage firm Citi sees minimal impact on Indian pharma firms
Mumbai, April 1: Global brokerage firm Citi said on Tuesday there is a low likelihood of the US imposing tariffs on Indian pharmaceuticals, despite ongoing discussions around the issue.
Indian pharma firms may gain market share due to higher US tariffs: Report
Mumbai, March 28: Indian pharma companies may stand to gain market share due to the potential impact of US tariffs, according to a JPMorgan report.
Indian pharma market to grow 8-9 per cent in FY26: Report
New Delhi, March 10: Indian pharmaceuticals market is expected to grow 8-9 per cent year-on-year in FY26, according to a report on Monday.
US tariffs will have minimal impact on Indian pharma service companies like CDMOs: Report
New Delhi, March 10: Indian pharma companies like CDMOs (Contract Development and Manufacturing Organizations) will not see major disruptions from the proposed US tariffs of 10-25 per cent, according to a report by B&K Securities.
Pharma sector in focus at India-Vietnam business meet in Ho Chi Minh City
Ho Chi Minh, Mar 3: As many as 39 Indian pharma companies connected with more than 50 Vietnamese counterparts, holding productive discussions during an 'India-Vietnam Business-to-Business (B2B)' meeting on the pharmaceutical industry organised in Vietnam's Ho Chi Minh City on Monday.
Indian pharma sector sees growth at 8 pc CAGR, export rates spike by 9 pc in 2024: Report
New Delhi, Feb 28: The Indian pharma sector has grown at 8 per cent CAGR and has also seen a 9 per cent increase in export rates in 2024, according to a report.
Indian CRDMO sector set to touch USD 22-25 billion by 2035: Report
New Delhi, February 25: The Indian Contract Research, Development, and Manufacturing Organization (CRDMO) sector is expected to touch USD 22 billion to USD 25 billion by 2035, according to a report by the Boston Consulting Group (BCG) and Innovative Pharmaceutical Services Organization (IPSO).
India's CDMO market set to double by 2028 amid Asia's healthcare boom
New Delhi, February 9: India's Contract Development and Manufacturing Organization (CDMO) market is poised for exponential growth, expected to expand from USD 7 billion to USD 14 billion by 2028, capturing 4-5 per cent of the global market, according to BCG report.
India reaffirms commitment to global Pharmaceutical standards at the 15th IMWP
New Delhi, February 5: Union Minister of State for Health and Family Welfare, Anupriya Patel, delivered the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the Ministry of Health and Family Welfare, Government of India, in collaboration with the World Health Organisation (WHO), on Wednesday, according to the official statement.
Budget 2025: India Pharmaceutical Alliance welcomes exemptions, concessions on essential drugs
By Shalini Bhardwaj, New Delhi, February 1: The Indian Pharmaceutical Alliance (IPA) has welcomed the Union Budget 2025, emphasising the government's 'commitment' towards sustainable and equitable healthcare through targeted reforms.
'Extremely grateful for recognition': Zydus Lifesciences Chairman elated over Padma Bhushan honour
New Delhi, Jan 26: Chairman of Zydus Lifesciences, Pankaj Patel, on Sunday thanked the Government for bestowing Padma Bhushan upon him, and said he was “extremely grateful for the recognition”.
Indian Pharma Industry to see negative volume growth in 3Q 2025, but will maintain strong gross margins: Report
New Delhi, January 13: The Indian pharmaceutical market (IPM) has returned to negative volume growth this Q3FY25 after two consecutive quarters of modest positive growth, according to Goldman Sachs report.
Robust earnings growth to continue in healthcare sector in Q3FY25: Report
New Delhi, January 7: Pharma companies in India are expected to report healthy earnings growth in the just-concluded October-December quarter, averaging 19.4 per cent, as per a report by brokerage firm Motilal Oswal.